Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.25 -0.44 (-0.98%)
Streaming Delayed Price Updated: 12:14 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year. 
Via The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too. 
Via The Motley Fool
Recap: Exelixis Q4 Earnings
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Preview For Exelixis
Via Benzinga
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
The 3 Best Biotech Stocks to Buy in February 2024
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes. 
Via InvestorPlace
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL, a growth stock which is not overvalued. 
Via Chartmill
Breaking Down Exelixis: 7 Analysts Share Their Views
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
3 Attractive Medical Stocks To Buy After Earnings
Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare... 
Via Talk Markets
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
From Exelixis, Inc.
Via Business Wire
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024. 
Via InvestorPlace
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.